This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/GRP865. CME credit will be available until November 8, 2024.

Reversal of Misfortune: Practical Insights for Managing Uncontrolled FXa-Inhibitor–Related Bleeding

In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support
This activity is supported by an independent educational grant from AstraZeneca LP.

Disclosure Policy
All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures
Co-Chair/Planner
Truman J. Milling Jr., MD, FACEP, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AstraZeneca; Cellphire, Inc.; CSL Behring; and Octapharma USA, Inc.
Honoraria from AstraZeneca; Cellphire, Inc.; CSL Behring; and Octapharma USA, Inc.


Co-Chair/Planner
W. Frank Peacock, MD, FACEP, FACC, FESC, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Abbott; BRAINBox Solutions, Inc.; F. Hoffmann-La Roche Ltd; Instrument Labs; Janssen Pharmaceuticals, Inc.; Osler; Siemens; Spinchip AS; and Vifor Pharma, Inc.
Grant/Research Support from BRAINBox Solutions, Inc. and Quidel Corporation.


Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.